Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-219X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples ; volume:9 ; number:1 ; day:3 ; month:6 ; year:2019 ; pages:1-7 ; date:12.2019
EJNMMI Research ; 9, Heft 1 (3.6.2019), 1-7, 12.2019
- Urheber
-
Schollhammer, Romain
Clermont Gallerande, Henri De
Yacoub, Mokrane
Quintyn Ranty, Marie-Laure
Barthe, Nicole
Vimont, Delphine
Hindié, Elif
Fernandez, Philippe
Morgat, Clément
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13550-019-0517-6
- URN
-
urn:nbn:de:101:1-2019092011003769378589
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schollhammer, Romain
- Clermont Gallerande, Henri De
- Yacoub, Mokrane
- Quintyn Ranty, Marie-Laure
- Barthe, Nicole
- Vimont, Delphine
- Hindié, Elif
- Fernandez, Philippe
- Morgat, Clément
- SpringerLink (Online service)
Ähnliche Objekte (12)
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
PET-bildgebendes Ansprechen einer Tandem 225Ac-PSMA-617/177Lu-PSMA-617- Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
Wirksamkeit und Sicherheit der Radioligandentherapie mit 177Lu-PSMA-617 bei Patienten mit mCRPC und niedriger PSMA-Expression
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Refined chelator spacer moieties ameliorate the pharmacokinetics of PSMA-617
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
PET-bildgebendes Ansprechen einer Tandem 225Ac-PSMA-617/177Lu-PSMA-617- Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
Wirksamkeit und Sicherheit der Radioligandentherapie mit 177Lu-PSMA-617 bei Patienten mit mCRPC und niedriger PSMA-Expression
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Refined chelator spacer moieties ameliorate the pharmacokinetics of PSMA-617
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
PET-bildgebendes Ansprechen einer Tandem 225Ac-PSMA-617/177Lu-PSMA-617- Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
Wirksamkeit und Sicherheit der Radioligandentherapie mit 177Lu-PSMA-617 bei Patienten mit mCRPC und niedriger PSMA-Expression
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Refined chelator spacer moieties ameliorate the pharmacokinetics of PSMA-617
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007